skip navigation nih record
Vol. LXI, No. 23
November 13, 2009

previous story

next story

Trans-NIH Global Health Research Effort Launched

NIH director Dr. Francis Collins (fourth from l) urged members of the new trans-NIH working group on global health research to find better ways to leverage resources and coordinate international activities to improve human health.
NIH director Dr. Francis Collins (fourth from l) urged members of the new trans-NIH working group on global health research to find better ways to leverage resources and coordinate international activities to improve human health.

NIH should capitalize on the current supportive environment for global health science, its director Dr. Francis Collins recently urged members of the newly created trans-NIH global health research working group.

“Our country is poised to move from the hard power stance to soft power or, as Hillary Clinton said, smart power. Shouldn’t we at NIH be leading that charge?” he asked.

The high-level working group is the result of a 2-year effort by institute and center directors to analyze global health research activities at NIH and explore better ways to coordinate efforts, both across NIH and throughout government. The Obama administration has pledged $63 billion to its Global Health Initiative and is seeking input on its approach.

“If we don’t step forward and point out the value of research, the focus is likely to be increasingly on delivery, which of course is critical,” Collins noted. “But we need the research aspect of this to be vigorously supported.”

The genesis of the working group was the previous NIH director’s leadership forum in 2007, during which a white paper was commissioned to detail the agency’s role in global health. Its recommendations guided a day-long discussion by NIH global health leaders last May.

Fogarty International Center director Dr. Roger Glass, who also serves as NIH associate director for international research, reported to IC directors in June and received their support to form the standing working group on global health research.

Representatives of 18 ICs and the Office of the Director participated in the group’s inaugural session, co-chaired by Glass.

Participants agreed to focus on three overarching issues—improving data collection on NIH international activities, ensuring clinical trials supported by NIH meet the highest possible standards no matter where they take place and developing strategies to position NIH to play a strategic role in the U.S. government’s global health activities.

“When I came here to Fogarty, we had no data on NIH’s commitments and investments in global health nor on the different areas of the world where people are invested and what they are doing,” Glass recounted.

There is still no comprehensive system to track foreign investments made by NIH, acknowledged Dr. Sally Rockey, acting director of the Office of Extramural Research.

Foreign sites that receive direct awards from NIH are captured in the system but foreign components of domestic awards are not, she said. “We want to strengthen our database so we can understand the funding gaps.”

Rockey said a possible solution may involve creating a new category that grantees would be required to use to report on foreign segments of domestic grants.

She agreed to co-chair a subcommittee on data collection issues with Dr. Jim Herrington, Fogarty’s international relations director.

A trans-NIH framework to assist the planning and implementation of international research projects was suggested by Dr. Susan Shurin, acting NICHD director.

It could collect best clinical research practices and other guidance by country or region, including advice on developing partnerships with NGOs and other governments. Other issues such as regulatory requirements, tissue specimen movement and human subjects’ protection could also be provided, she said.

Such shared information could reduce the time for contract negotiations on foreign projects, encourage IRB reciprocity and help recruit clinical trial participants, noted NCRR director Dr. Barbara Alving. A virtual “concierge of experts” could also be assembled to provide useful on-the-ground experience to other investigators.

A second subcommittee, led by Shurin and Dr. Hugh Auchincloss, deputy director of NIAID, will develop the clinical trials resource.

It was also decided the group will convene country-specific meetings to facilitate inter-IC collaboration and share best practices for engaging a specific country.

The full working group is scheduled to meet again in December.

Collins told the group their work could prove to be significant and that he’d be cheering them on. “It’s a great scientific opportunity and it fits so well with what NIH is all about—which is science to serve the public, in this case the whole public.” NIHRecord Icon

back to top of page